Halozyme Therapeutics HALO Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| —— | —— | $595.49M+51.7% | $557.28M+65.2% | $485.36M+52.2% | ||
| $12.93M+22.6% | $11.39M+10.6% | $10.74M+1.6% | $10.64M-0.3% | $10.54M-3.1% | ||
| $57.53M+30.2% | $51.57M+18.9% | $46.46M+11.7% | $46.87M+22.1% | $44.18M+14.7% | ||
| —— | —— | —— | —— | —— | ||
| —— | $48.7M— | $36.53M— | $24.35M— | $12.18M— | ||
| $151.44M+39.3% | $128.06M+72.5% | $60.29M-11.9% | $101.82M+422% | $108.72M+8,811% | ||
| -$30.52M-203% | -$2.55M-104% | $23.95M— | $22.85M— | $29.71M— | ||
| -$27.93M-174% | $6.21M-86.8% | $22.55M+278% | $6.53M-23.7% | $37.53M— | ||
| —— | —— | $55.76M— | -$3.04M— | $4.43M— | ||
| $88.41M+24.4% | $76.66M+7.9% | $71.05M0.0% | $71.05M-3.5% | $71.05M-3.6% | ||
| $7.91M+7.3% | $7.51M+2.1% | $7.4M+0.9% | $7.38M+0.9% | $7.37M+0.9% | ||
| $677.42M+34.4% | $651.56M+36.0% | $611M+51.6% | $547.78M+30.4% | $503.86M+16.9% | ||
| $9.76M+20.5% | $6.97M-34.8% | $8.6M-16.1% | $7.08M-39.3% | $8.1M— | ||
| $116.56M-80.2% | $247.36M-61.8% | $298.8M-51.6% | $597.82M+25.8% | $588.48M+54.2% | ||
| $681.08M+109% | $722.25M+82.6% | $532.85M+62.9% | $461.26M+70.6% | $326.11M+20.9% | ||
| —— | $284.89M— | $213.67M— | $142.44M— | $71.22M— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | -$571.1M-157% | -$530.14M— | -$221.69M— | ||
| —— | —— | $265.35M+321% | -$126M-278% | $11.7M— | ||
| —— | $11.43M+8.2% | $11.21M+4.1% | $11M+0.1% | $10.78M-3.7% | ||
| —— | $134.64M+67.0% | $121.14M+77.1% | $107.63M+91.6% | $94.12M+114% | ||
| $1.62M-84.2% | $3.3M-69.8% | $5.6M-49.2% | $8.36M-10.8% | $10.26M+32.1% | ||
| $7.91M+7.3% | $7.51M+2.1% | $7.4M+0.9% | $7.38M+0.9% | $7.37M+0.9% | ||
| $88.41M+24.4% | $76.66M+7.9% | $71.05M0.0% | $71.05M-3.5% | $71.05M-3.6% | ||
| -$912K+17.1% | -$951K+10.9% | -$884K+58.6% | -$1.07M+7.8% | -$1.1M+6.0% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | $55.76M— | -$3.04M— | $4.43M— | ||
| —— | $284.89M— | $213.67M— | $142.44M— | $71.22M— | ||
| —— | $287.77M— | $215.83M— | $143.89M— | $71.94M— | ||
| —— | —— | —— | —— | —— | ||
| —— | $722.25M+82.6% | $640.58M+83.3% | $558.91M+84.2% | $477.24M+85.4% | ||
| —— | —— | —— | —— | —— | ||
| —— | $5.48M— | $4.11M— | $2.74M— | $1.37M— | ||
| —— | —— | —— | $2.34M-21.9% | $1.93M-43.3% | ||
| —— | $134.64M+67.0% | $121.14M+77.1% | $107.63M+91.6% | $94.12M+114% | ||
| $667.65M+34.7% | $644.59M+37.6% | $602.4M+53.4% | $540.69M+32.4% | $495.76M+17.0% | ||
| $667.65M+34.7% | $644.59M+37.6% | $602.4M+53.4% | $540.69M+32.4% | $495.76M+17.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Halozyme Therapeutics generate?
- Halozyme Therapeutics (HALO) generated $677.4M in operating cash flow over the trailing twelve months.
- What is Halozyme Therapeutics's free cash flow?
- After $9.8M of capital expenditures, Halozyme Therapeutics's free cash flow was $667.7M over the trailing twelve months, up 34.7% year over year.
- Where does Halozyme Therapeutics's cash flow data come from?
- Every line is extracted from Halozyme Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
